STUMP un"stumped": Anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Subbiah, Vivek ^a   McMahon, Caitlin ^b   Patel, Shreyaskumar ^a   Zinner, Ralph ^a   Silva, Elvio G ^a   Elvin, Julia A ^b   Subbiah, Ishwaria M ^a   Ohaji, Chimela ^a   Ganeshan, Dhakshina Moorthy ^a   Anand, Deepa ^a   Levenback, Charles F ^a   Berry, Jenny ^a   Brennan, Tim ^b   Chmielecki, Juliann ^b   Chalmers, Zachary R ^b   Mayfield, John ^b   Miller, Vincent A ^b   Stephens, Philip J ^b   Ross, Jeffrey S ^b   Ali, Siraj M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOUNDATION MEDICINE   (United States)

Author keywords

ALK; ALK fusions; Crizotinib; Inflammatory myofibroblastic tumor; Pazopanib; Sarcoma; Smooth muscle tumor of uncertain malignant potential (STUMP); Targeted therapy; Uterine myxoid tumors

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; DCTN1 ALK FUSION PROTEIN; GENOMIC DNA; HYBRID PROTEIN; PAZOPANIB; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADULT; ARTICLE; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DCTN1 ALK GENE; DISEASE ASSOCIATION; DISEASE COURSE; DNA HYBRIDIZATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FEMALE; FUSION GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYXOID TUMOR; OMENTECTOMY; ONCOGENE; PATIENT ASSESSMENT; PELVIS LYMPHADENECTOMY; PLASMA CELL GRANULOMA; SALPINGOOOPHORECTOMY; SEQUENCE ANALYSIS; SMOOTH MUSCLE TUMOR OF UNCERTAIN MALIGNANT POTENTIAL; SOLID TUMOR; UTERUS TUMOR; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; GENE FUSION; GENETICS; GENOMICS; MESENCHYMOMA; METABOLISM; PATHOLOGY; UTERUS CANCER;

BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE FUSION; GENOMICS; HUMANS; MESENCHYMOMA; MIDDLE AGED; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; UTERINE NEOPLASMS;

EID: 84935825445     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0160-2     Document Type: Article

References (30)

1. Zulfiqar MI, Sheikh UN, Montgomery EA. Myxoid neoplasms. Surg Pathol Clin. 2011;4:843-64.
2. Frampton GM, Fitchtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-31.
3. Zinner R. Pazopanib or pemetrexed and crizotinib in advanced cancer. (M.D. Anderson Cancer Center). at https://clinicaltrials.gov/ct2/show/NCT01548144.
4. Marino-Enriquez A, Dal CP. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genet. 2013;206:357-73.
5. Wang X, Krishnan C, Nguyen EP, Meyer KJ, Oliverira JL, Yang P, et al. Fusion of dynactin 1 to anaplastic lymphoma kinase in inflammatory myofibroblastic tumor. Hum Pathol. 2012;43:2047-52.
6. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. Kinase fusions are frequent in Spitz tumors and spitzoid melanomas. Nat Commun. 2014;5:3116.
7. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281-4.
8. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8.
9. Allen PW. Myxoid tumors of soft tissues. Pathol Annu. 1980;15:133-92.
10. Mackenzie DH. The myxoid tumors of somatic soft tissues. Am J Surg Pathol. 1981;5:443-58.
11. Graadt van Roggen JF, Hogendoorn PC, Fletcher CD. Myxoid tumours of soft tissue. Histopathology. 1999;35:291-312.
12. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14:569-76.
13. Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014;4:889-95.
14. Fraggetta F, Doglioni C, Scollo P, Pecciarini L, Ippolito M, Amico P, et al. Uterine inflammatory myofibroblastic tumor in a 10-year-old girl presenting as polypoid mass. J Clin Oncol. 2015;33.
15. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008;61:428-37.
16. Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001;25:1364-71.
17. Kushnir CL, Gerardi M, Banet N, Shih I-M, Diaz-Montes T. Extrauterine inflammatory myofibroblastic tumor: a case report. Gynecol Oncol Case Rep. 2013;6.
18. Parra-Herran C, Quick CM, Howitt BE, Dal Cin P, Quade BJ, Nucci MR. Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course. Am J Surg Pathol. 2015;39:157-68.
19. Fuehrer NE, Keeney GL, Ketterling RP, Knudson RA, Bell DA. ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract. Arch Pathol Lab Med. 2012;136:623-6.
20. Melloni G, Carretta A, Ciriaco P, Arrigoni G, Fieschi S, Rizzo N, et al. Inflammatory pseudotumor of the lung in adults. Ann Thorac Surg. 2005;79:426-32.
21. Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472-80.
22. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-703.
23. Ou SH, Kwak EL, Siawak-Tapp C, Dy J, Bergethon K, Clark JW, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6:942-6.
24. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-70.
25. Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363:1727-33.
26. Lorenzi L, Cigognetti M, Medicina D, Pellegrini V, Balzarini P, Cestari R, et al. ALK-positive inflammatory myofibroblastic tumor of the abdomen with widespread microscopic multifocality. Int J Surg Pathol. 2014;22:640-4.
27. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30-9.
28. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-94.
29. Stinchcombe, T. E. Recent advances in the treatment of non-small cell and small cell lung cancer. F1000Prime Rep. 2014;6:117.
30. Van Geel RM, Beijnen JH, Schellens JH. Concise drug review: pazopanib and axitinib. Oncologist. 2012;17:1081-9.